Instead, researchers found that treatment with supra-pharmacological concentrations of metformin can decrease adenosine diphosphate (ADP) levels by reduction of adenine synthesis and that the addition of exogenous adenosine diphosphate could restore inhibited mitochondrial oxygen consumption by the supra-pharmacological metformin concentrations (Wang et al., 2019)
The Gray Market and Research Chemical Status In the legal landscape of many countries, BPC-157 exists in a gray area commonly referred to as a "research chemical." In this category, the compound can be manufactured, imported, and sold in certain jurisdictions with labeling disclaimers such as "for research purposes only" or "not for human consumption." This labeling is technically a legal requirement in some regions, but it doesn't prevent individuals from purchasing and using BPC-157 outside official medical channels
These multi-omics findings were further translated to human disease when Wfdc2 was validated as a potential biomarker in DKD patient samples (Shi et al., 2023a)
However, these projects are not without criticism, and one significant area of concern involves their social consequences
